Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease

Dongliang Lv, Peng Feng, Xueying Guan, Zhaona Liu, Dongfang Li, Cunshui Xue, Bo Bai, Christian Hölscher · 2024

Read Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease by Dongliang Lv, Peng Feng, Xueying Guan, Zhaona Liu, Dongfang Li, Cunshui Xue, Bo Bai, Christian Hölscher (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11667896.txt.

Description

Dongliang Lv and co-authors review evidence that diabetes drugs of the GLP-1 class might slow Parkinson's disease, in a paper published in 2024. Parkinson's robs the brain of dopamine and steadily impairs movement, and current drugs ease symptoms without slowing the disease. The two conditions share suspicious features: insulin resistance, chronic inflammation, and failing mitochondria.

GLP-1 receptor agonists, the team notes, cross into the brain, improve insulin signaling, steady mitochondria, and help neurons survive. They also calm inflammation and oxidative stress, both central to degeneration. Early research hints at benefits for motor and non-motor symptoms alike. The review assembles the mechanisms that make these drugs plausible candidates for the first treatment that changes Parkinson's course.

Catalog record

CREATORDongliang Lv, Peng Feng, Xueying Guan, Zhaona Liu, Dongfang Li, Cunshui Xue, Bo Bai, Christian Hölscher
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11667896

Browse the full library · About the Tower of Babel